Therapeutic Advances in Medical Oncology: 2024, vol: 16, issue:
- 1)- Qianming Bai, Xiaohua Shi, Xiaoyan Zhou, Zhiyong Liang, Shun Lu, Yilong Wu. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer. Therapeutic advances in medical oncology. 2024, 16: 17588359231216096
Cited : 1Read More - 2)- Yohei Kubota, Kohei Shitara. Zolbetuximab for Claudin18.2-positive gastric or gastroesophageal junction cancer. Therapeutic advances in medical oncology. 2024, 16: 17588359231217967Cited : 5Read More
- 3)- Yuehua Liang, Xiaoran Liu, Zehui Yun, Kun Li, Huiping Li. Endocrine therapy plus HER2-targeted therapy, another favorable option for HR+/HER2+ advanced breast cancer patients. Therapeutic advances in medical oncology. 2024, 16: 17588359231220501Cited : 2Read More
- 4)- Jian Pan, Tingwei Zhang, Shouzhen Chen, Ting Bu, Jinou Zhao, Xudong Ni, Benkang Shi, Hualei Gan, Yu Wei, Qifeng Wang, Beihe Wang, Junlong Wu, Shaoli Song, Feng Wang, Chang Liu, Dingwei Ye, Yao Zhu. Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study. Therapeutic advances in medical oncology. 2024, 16: 17588359231220506Cited : 3Read More
- 5)- Xiaolei Liu, Ruiquan Zhou, Liguo Liu, Shuang Si, Shiwei Yang, Dongdong Han, Haidong Tan. Short-term outcomes of combined therapy with sirolimus and interferon-alpha 2b for advanced hepatic epithelioid hemangioendothelioma. Therapeutic advances in medical oncology. 2024, 16: 17588359231220509Cited : 1Read More
- 6)- Nithya Krishnamurthy, Daisuke Nishizaki, Scott M Lippman, Hirotaka Miyashita, Mary K Nesline, Sarabjot Pabla, Jeffrey M Conroy, Paul DePietro, Shumei Kato, Razelle Kurzrock. High CTLA-4 transcriptomic expression correlates with high expression of other checkpoints and with immunotherapy outcome. Therapeutic advances in medical oncology. 2024, 16: 17588359231220510Cited : 3Read More
- 7)- Junli Xue, Liqiong Xue, Wenbo Tang, Xiaoxiao Ge, Wei Zhao, Qun Li, Wei Peng, Congqi Dai, Ye Guo, Jin Li. TQB2450 in patients with advanced malignant tumors: results from a phase I dose-escalation and expansion study. Therapeutic advances in medical oncology. 2024, 16: 17588359231220516Cited : 1Read More
- 8)- Jia-Jun Wu, Jeng-Sen Tseng, Zhe-Rong Zheng, Cheng-Hsiang Chu, Kun-Chieh Chen, Mong-Wei Lin, Yen-Hsiang Huang, Kuo-Hsuan Hsu, Tsung-Ying Yang, Sung-Liang Yu, Jin-Shing Chen, Chao-Chi Ho, Gee-Chen Chang. Primary tumor consolidative therapy improves the outcomes of patients with advanced -mutant lung adenocarcinoma treated with first-line osimertinib. Therapeutic advances in medical oncology. 2024, 16: 17588359231220606Cited : 0Read More
- 9)- XinYi Hong, ShanHu Qiu, Bo Ding, Hao Xu, Yang Shen. Combined use of Anlotinib with chemotherapy in patients with advanced ovarian cancer: a real-world cohort study and meta-analysis. Therapeutic advances in medical oncology. 2024, 16: 17588359231221336Cited : 1Read More
- 10)- Kaiqi Lan, Jingrong Mao, Xuesong Sun, Suchen Li, Siyi Xie, Rui Sun, Sailan Liu, Haiqiang Mai. Combined pre-treatment and middle-treatment Epstein-Barr virus DNA load contributes to prognostication and treatment modification in nasopharyngeal carcinoma patients. Therapeutic advances in medical oncology. 2024, 16: 17588359231221343Cited : 2Read More
